Dr. Keith Syson Chan received his PhD from the University of Texas, MD Anderson Cancer Center in 2004. He was trained under the classical concept that epithelial cancers develop via a multi-step process. Through pathologic evaluation of tumor tissues, he developed the appreciation that cancer is a disease of aberrant cellular differentiation. He then joined Prof. Irving Weissman’s laboratory at Stanford University to continue his postdoctoral studies (2004-09). He was amongst the first to isolate cancer stem cells (CSCs) from human bladder urothelial carcinomas, and investigated CD47 as a mechanism for immune evasion. Dr. Chan is currently an associate professor at Baylor College of Medicine, emphasizing on translating CSC-targeted therapeutics into human clinical trials.
Dr. Keith Syson Chan was amongst the first to isolate cancer stem cells (CSCs) from human bladder urothelial carcinomas, and investigated CD47 as a mechanism for immune evasion.
Dr. Ming Lei is a molecular geneticist by training. He earned his PhD degree from Cornell University and continued his postdoctoral training there. He was a faculty member at the Medical College of Wisconsin, where he taught Genetics and Microbiology to medical students and graduate students. He was a NIH funded principal investigator focusing his research efforts on the regulation of eukaryotic DNA replication. He began his governmental service in 2006 at the National Science Foundation, where he managed NSF’s research grant portfolio in Molecular Biology, Genetics and Genomics. He has been with the National Cancer Institute since 2008.
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.
Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.
Thierry Virolle is a Research Director (permanent position) at Institut National de la Santé et de la Recherche Médicale (INSERM), Head of the Team Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity at the Institute of Biologie Valrose (iBV). He is Co-Founder of the French National Sud Cancer Stem Cell Network, SUNRiSE dedicated to the study of cancer stem cell.
He is Doctor of Science (PhD) at Nice Sophia Antipolis University (2000), his researches focus on the regulation of the plasticity of glioblastoma cancer stem cells and its contribution in the genesis of functionally divergent tumor territories.
Guo-fu Hu, PhD, is currently a Professor of Medicine, Tufts University School of Medicine, and an Investigator at Tufts Medical Center. He received his PhD from Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and did his postdoctoral training in Beret L. Vallee lab located at the Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School. He established his research program first in the Department of Radiology, Brigham and Women’s Hospital, and then in the Department of Pathology, Harvard Medical School, where he raised to the rank of Associate Professor of Pathology. He moved to Tufts Medical Center in 2010.
Dr. Hu has been studying the mechanism and function of angiogenin in cancer and in angiogenesis for many years. His current focus is on the role of angiogenin and its receptor in regulating self-renewal and quiescence of stem cells, including hematopoietic stem cells and cancer stem cells.
Dr. Qien Wang is an Associatet Professor in the Department of Radiology and Comprehensive Cancer Center at the Ohio State University. Dr. Wang received his Bachelor Degree in Preventive Medicine in Shanxi Medical College in 1992, and obtained his PhD from Beijing Medical University in 1997 in China. Then, Dr. Wang worked as a Lecturer and Associate Professor at Peking University Medical Center for 4 years. During this time, his research was focused on understanding how gene and environmental exposure interact in carcinogenesis. In 2001, Dr. Wang joined Dr. Altaf Wani’s laboratory at the Ohio State University in the United States of America to study the mechanism of DNA repair as a Research Associate and Research Scientist. Since 2011, Dr. Wang has become a Tenure-track Assistant Professor at the Ohio State University, and was promoted to Associate Professor with Tenure in 2017.
Dr. Wang’s research is focused on a mechanistic understanding of cancer progression, metastasis and recurrence, particularly in term of cancer stem cells.
Dr. Jingfang Ju is the Professor in the Department of Pathology at Stony Brook Medicine/Stony Brook University. Dr. Ju received his BS degree from the Northeastern University and Ph.D. in molecular biology and biochemistry at the University of Southern California. He completed his post-doctoral research fellowship at Yale Cancer Center, Yale University. Previously Dr. Ju has served as the Senior Scientist and Team Leader of high throughput genomics at a biopharmaceutical company, CuraGen Corporation in Connecticut.
Dr. Ju's major research interest is in the development of miRNA based therapeutics and biomarker in gastrointestinal cancer. The Ju laboratory studies the mechanisms of microRNAs in cancer stem cell resistance, epithelial to mesenchymal transition (EMT), autophagy, and apoptosis. His group made initial discovery of the regulatory relationship between p53 tumor suppressor and microRNA. Dr. Ju and his group discovered the superior stability of microRNA in archival formalin fixed paraffin embedded (FFPE) clinical specimens which serves as the foundation of microRNA based biomarker discovery.
Hervé Chneiweiss, first trained as a neurologist (movement disorders, Parkinson), HC was involved in the neurogenetics of human diseases such as cerebellar ataxias. For the last 15 years his scientific work was dedicated to the biology of astrocytes and their roles in brain tumor progression. He created in 2006 the Inserm laboratory U752, which gathered scientists and clinicians devoted to the study of brain tumors. HC is since 2014 director of the laboratory Neuroscience Paris Seine.
Hervé Chneiweiss is studying molecular mechanisms involved in glial plasticity and underlying brain tumor development. Privileged technical expertise includes proteomics and cell cultures. Hervé Chneiweiss is also involved in bioethics and editor of Medecine/Sciences
After graduating from the Royal College of Surgeons in Ireland in 2004 with a PhD in Oncology, Stephen Maher spent 3 years as a visiting fellow at the National Cancer Institute in the US. In 2007 he returned to Ireland and Trinity College Dublin, St. James’s Hospital as a research fellow. In 2010 he established his own research group having secured an Irish Cancer Society Fellowship and a number of Health Research Board grants, predominantly in the area of radiation resistance in the treatment of gastrointestinal malignancy. In 2012 Stephen moved to the University of Hull and Hull York Medical School as a senior lecturer, where he led the Cancer Biology and Therapeutics lab. In 2016 Stephen returned to Trinity College Dublin as the James Ussher Assistant Professor in Translational Oncology, where he has set up new cancer radiobiology and hypoxia research cores.
At the Department of Surgery, based at TCD and St. James’s Hospital Dublin, Stephen is primarily interested in understanding the complex molecular mechanisms underpinning resistance to radiotherapy and chemotherapy in oesophageal adenocarcinoma and malignant pleural mesothelioma. He is currently examining the role of microRNAs and cancer stems cells in driving resistance to treatment, and researching microRNA replacement therapy as a novel therapeutic to augment patient responses to conventional cytotoxics.
Dr. Subhra Mohapatra has completed her PhD from University of Manitoba, Canada and postdoctoral studies at H. Lee Moffitt Cancer Center. Currently, she is an Associate Professor of Molecular Medicine in the Morsani College of Medicine, University of South Florida. During last 10 years, she has trained 13 postdocs and 16 graduate students involved in multidisciplinary research, such as biology, immunology, nanoscience and nanotechnology fields. She has authored over 62 scientific papers and holds 12 US patents. Her research is funded by the National Institute of Health, Veterans Administration and Florida Department of Health. She has been serving as an Academic Editor for the Plos One.
Our research is focused on understanding the role of stromal cells in the tumor microenvironment that play a critical role in tumor growth and recurrence. We use nanotechnology–integrated cellular and molecular approaches to dissect major signaling pathways in cancers and identify novel drug targets and biomarkers and experimental therapeutics for cancer. We have also synthesized 3D/4D polymeric nano/micro scaffolds for studying tumor-stroma interactions in modulating cancer stem cell expansion and anticancer drug targets. We are also investigating the mechanism of anti-inflammatory triggers for traumatic brain injury.
A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.
Associate Professor Li’s research is aimed at a): To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.
Joo-Hyeon Lee was fascinated by stem cell research through Ph.D. studies under the supervision of Prof. Daesik Lim in KAIST, Korea. She then joined Prof. Carla Kim’s laboratory at Harvard Medical School where she became interested in the study of adult lung stem cells. She established her own research group at the Cambridge Stem Cell Institute in 2016 and focuses on understanding cellular behavior and regulatory networks of adult stem and niche cells. Joo-Hyeon is currently Faculty member at the Department of Physiology, Development, and Neuroscience, University of Cambridge and was recently awarded the Royal Society and Wellcome Trust Sir Henry Dale Fellowship and ERC starting grant.
Lee lab applies mouse genetics, ex vivo organoid co-cultures, live imaging, single-cell molecular analysis and mathematic modelling to define the identity and heterogeneity of diverse epithelial progenitor and mesenchymal populations, understand the key stem-mesenchymal interactions and the precise mechanisms that maintain tissue homeostasis and regeneration. Specifically, they are asking how the quiescent state is maintained and becomes activated, how cell fate is determined, and how niches develop and remodel in lung homeostasis, injury repair and early tumorigenesis.
Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.
Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.
Dr. Elaine Hurt received her PhD in Biochemistry, Molecular Biology and Biophysics from the University of Minnesota in 1999 where she studied estrogen receptor signaling cascades. Dr. Hurt did her post-doctoral studies at the National Institutes of Health in the laboratory of Dr. Louis Staudt elucidating the molecular mechanisms governing therapeutic responses in lymphoma and multiple myeloma patients. In 2010, Dr. Hurt joined MedImmune to lead their cancer stem cell group. Prior to joining MedImmune, Dr. Hurt was a Staff Scientist at the National Cancer Institute, where she focused primarily on identifying and targeting prostate cancer stem cells. In 2014, Dr. Hurt became Adjunct Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Maryland. She is the co-inventor on several patents, has been an invited speaker at numerous conferences, and has published over 50 scientific articles.
Dr. Hurt’s research is aimed at developing novel therapeutics to treat cancer. In particular, she is focused on understanding and developing targets against cancer stem cells. In recent years, there is a focus on understanding how cancer stem cells shape and interact with the immune cells of tumor microenvironment.
Dr. Ralf Huss joined Definiens in 2013 and has more than 20 years of training and experience in histopathology and cancer research. Dr. Huss also co-founded the biotech company APCETH. He has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.
He has training and experience in immunology, transplantation biology and stem cell research and also involved in identifying new tissue biomarkers to stratify cancer patients.
Dr. Xianming Mo is a professor of internal medicine and acts as Director of Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He obtained his medicine degree from North Sichuan Medical College. Then he was trained in pathology and accept Master of Medicine in West China University of Medical Science. After obtaining a PhD degree in Peking Union Medical College, He moved to Humboldt-Universität zu Berlin and then to Medical College of Georgia as postdoctoral fellows. Then, he became junior faculty in Medical College of Georgia and senior scientist in Max Delbruck Center for Molecular Medicine. In 2006, he returned back to West China Hospital.
Xianming Mo is interested in understanding the biology of physiological and pathological tissue stem cells including hematopoietic stem cell, neural stem cell and epithelial stem cells. Now one of his works focuses on the biology of the cancer stem cells, the constitution of cancer tissues in human patients with carcinoma and the their therapeutic implications in cancer.
Emmanuelle Charafe-Jauffret is a doctor of medicine and a specialist in breast cancer, and is known for her expertise in cancer stem cells.
She led a group on the characterization of cancer stem cells in the gland breast.
Laurie J. Gay earned her Ph.D. at The Scripps Research Institute in La Jolla, California as a NIH Clinical and Translational Science Award Scholar. During this time, her research focused on the creation of metastasis models for understanding systemic and host influences on distant tumor development, especially brain metastasis. In 2013, she joined the laboratory of Dr. Ilaria Malanchi in her current position of Cancer Research UK Postdoctoral Fellow at the London Research Institute (now part of the Francis Crick Institute) in London.
Laurie J. Gay is a cancer biologist with 11 years of pre-clinical research experience in oncology, with a focus on molecular mechanisms of tumor progression and metastasis.
Emilie Mamessier performed her Ph.D. at Aix-Marseille University, followed by a postdoc at the Institute for Child health Research in Perth (Pr. P Holt, Australia) working on deregulated immune responses in asthma. Ten years ago, she switched to study cancer development, notably with the characterization of early stages of cancer, both at the tumor cell level and in relation to tumor microenvironment composition (CRCM and Center of Immunology Marseille Luminy CIML, Marseille).
Emilie Mamessier research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.